Keros Therapeutics, Inc. filings document a clinical-stage biopharmaceutical issuer developing therapeutics that modulate transforming growth factor-beta family signaling. Its 8-K reports cover financial results, Regulation FD corporate presentations, clinical-program announcements, collaboration disclosures, and board composition changes, while exchange registration disclosures identify Nasdaq-listed common stock and preferred share purchase rights.
The company’s proxy materials describe stockholder voting matters, board and committee governance, director compensation, and executive compensation. They also disclose portfolio strategy, including prioritization of rinvatercept, discontinued internal development activities for cibotercept, and related governance oversight of the company’s research and development focus.
Keros Therapeutics director Alpna Seth reported an open-market sale of 2,625 shares of common stock at a weighted average price of $10.72 per share on June 4, 2026. The shares were sold in multiple trades between $10.60 and $10.89. After this transaction, she directly holds 9,767 shares. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on December 9, 2025, indicating the timing was planned in advance.
Keros Therapeutics director Mary Ann Gray received new equity awards. She was granted 7,142 shares of common stock in the form of restricted stock units that fully vest on the earlier of June 3, 2027 or the 2027 annual meeting, subject to continued service. She also received options for 7,433 shares at an exercise price of $10.50 per share, vesting in equal quarterly installments over 12 months after June 3, 2026 and fully vested by the 2027 annual meeting. Following the RSU grant, she directly holds 12,392 common shares.
Keros Therapeutics director Nima Farzan reported equity awards that increase his direct stake in the company. He received 7,142 shares of common stock through a restricted stock unit (RSU) grant, bringing his direct common stock holdings to 12,392 shares.
The RSUs fully vest on the earlier of June 3, 2027 or the company’s 2027 annual meeting of stockholders, if he continues to provide service. He was also granted a stock option for 7,433 shares at an exercise price of $10.50 per share, vesting in equal quarterly installments over the 12 months following June 3, 2026 and in any case fully vested by the 2027 annual meeting, subject to continued service. These are compensation-related awards rather than open-market purchases or sales.
Keros Therapeutics director Jean Jacques Bienaime reported equity awards rather than open-market trades. He received 7,142 shares of Common Stock as a restricted stock unit award, bringing his direct Common Stock holdings to 16,592 shares. The filing also shows a grant of options for 7,433 shares of Common Stock at an exercise price of $10.50 per share. The RSUs fully vest on the earlier of June 3, 2027 or the company’s 2027 annual meeting of stockholders, while the options vest in equal quarterly installments over 12 months following June 3, 2026 and in any case are fully vested by the 2027 annual meeting, in each case subject to continued service.
Keros Therapeutics director Julius Knowles reported new equity awards and updated his holdings. He received 7,142 restricted stock units that vest on the earlier of June 3, 2027 or the company’s 2027 annual meeting of stockholders, as long as he continues serving the company.
He also received a stock option covering 7,433 shares of common stock at an exercise price of $10.50 per share. This option vests in equal quarterly installments over the 12 months following June 3, 2026 and will in any case be fully vested by the 2027 annual meeting, subject to continued service. After these grants, he directly holds 13,583 common shares and also has indirect interests in 102,233 and 150,047 shares held by Partners Innovation Fund, LLC and Partners Innovation Fund II, L.P., where he may share voting and investment power.
Keros Therapeutics, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 3, 2026. A quorum was present and stockholders voted on director elections, auditor ratification and an advisory say-on-pay resolution.
Stockholders elected Jean-Jacques Bienaimé and Charles Newton as directors to serve until the 2029 Annual Meeting and until their successors are duly elected and qualified. They also ratified Deloitte & Touche LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
In addition, stockholders approved, on a non-binding advisory basis, the compensation of the company’s named executive officers as described in the April 22, 2026 proxy statement.
Keros Therapeutics, Inc. announced that President and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026 at 4:00 p.m. Eastern time.
A live audio webcast and an archived replay for up to 90 days will be available through links on the Investors section of the Keros website. The company is described as a clinical-stage biopharmaceutical business focused on therapeutics targeting dysfunctional signaling of the transforming growth factor-beta family of proteins, with lead candidates rinvatercept and elritercept in development for serious neuromuscular and hematologic disorders.